$PRGO (Perrigo Company Public Limited Company)

$PRGO {{ '2016-04-06T17:58:14+0000' | timeago}} • SEC

$PRGO's effective tax rate on continuing operations was 124.2% for the six months ended Dec. 31, 2015. This was significantly higher due mainly to the foreign tax rate impacts recorded at higher than the Irish tax rate for the impairment of Omega's intangible assets and the company's India API assets held for sale.

$PRGO {{ '2017-07-19T14:24:45+0000' | timeago}} • Announcement

$PRGO received final approval from the US FDA for its AB rated ANDA referencing DermOtic Oil, 0.01% Ear Drops. The company expects to launch this product within 90 days. DermOtic Oil, 0.01% Ear Drops are indicated for the treatment of chronic eczematous external otitis in adults, and children two years old and older.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$PRGO {{ '2017-07-17T13:28:38+0000' | timeago}} • Announcement

$PRGO's subsidiary filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Soolantra (ivermectin) cream, 1%. The cream is indicated for the treatment of inflammatory lesions of rosacea.

$PRGO {{ '2017-06-21T12:47:31+0000' | timeago}} • Announcement

$PRGO launched its generic equivalents to Hill Laboratories Inc.'s Derma-Smoothe/FS Scalp Oil and Derma-Smoothe/FS Body Oil. These are indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to four weeks.

$PRGO {{ '2017-06-14T17:53:40+0000' | timeago}} • Announcement

$PRGO announced the reference yield and total consideration for each series of notes subject to the previously announced cash tender offer for up to a combined aggregate principal amount of $1.4Bil of Perrigo's notes.

$PRGO {{ '2017-06-14T12:01:20+0000' | timeago}} • Announcement

$PRGO announced the early tender results as of June 13, 2017 for cash tender offer for up to combined amount of $1.4Bil of  4% Notes due 2023 and 5.3% Notes due 2043 and Perrigo Finance Unlimited's subsidiary 3.5% Notes due March 2021, 3.5% Notes due December 2021, 4.9% Notes due 2044, 4.375% Notes due 2026 and 3.9% Notes due 2024.

$PRGO {{ '2017-06-06T13:09:31+0000' | timeago}} • Announcement

$PRGO announced the forthcoming retirement of CEO John Hendrickson. Hendrickson will continue to stand for election to its BoD at its Annual General Meeting on July 20, 2017 and will step down from the Board upon the appointment of a new CEO.

$PRGO {{ '2017-06-06T13:08:55+0000' | timeago}} • Announcement

$PRGO announced the forthcoming retirement of CEO John Hendrickson. Hendrickson will remain with the company until his replacement is appointed, as well as up to 60 days following to ensure a smooth and successful transition.

$PRGO {{ '2017-06-06T13:07:17+0000' | timeago}} • Announcement

$PRGO announced the forthcoming retirement of CEO John Hendrickson. A search committee of the BoD has been created and will begin conducting a thorough process to identify Hendrickson's replacement.

$PRGO {{ '2017-05-31T14:06:01+0000' | timeago}} • Webcast

When asked about the current status of Rx business review process, $PRGO stated that it has not set a date for the conclusion. The company expects to bring the generic version of asthma drug ProAir in the market in calendar year 2018. $PRGO does not expect another generic entrant for ProAir until mid-2019.

$PRGO {{ '2017-05-31T13:24:02+0000' | timeago}} • Webcast

$PRGO continues to expect adjusted EPS to be weighted towards the second half of the calendar year 2017. This is driven by the timing of cost initiatives, debt paydown strategy and margin contribution from new product launches. The company expects to launch over 100 new products in 2017. New product sales are expected to be greater than $200MM.

$PRGO {{ '2017-05-31T12:57:43+0000' | timeago}} • Announcement

$PRGO continues to expect CY17 net sales to be in the range of $4.6-4.8Bil. GAAP diluted EPS is expected to be in the range of $1.82-2.17 and the company continues to expect adjusted diluted EPS to be in the range of $4.15-4.50, including contributions from the Israel API business and excluding the charges.

$PRGO {{ '2017-05-31T12:56:14+0000' | timeago}} • Announcement

$PRGO's sales for 1Q17 decreased 11% from last year. This was primarily due to lower year-over-year contributions from net sales of existing products, the U.S. Vitamin, Mineral, and Supplement (VMS) business, the exit of the European distribution businesses, Entocort, unfavorable foreign currency movements and discontinued products.

$PRGO {{ '2017-05-31T12:54:35+0000' | timeago}} • Announcement

$PRGO swung to a profit in 1Q17 from a loss last year, on lower impairment charges, as well as lower costs and expenses. Net income was $72MM or $0.50 per share compared to a loss of $529MM or $3.70 per share last year. Sales fell to $1.19Bil from $1.35Bil. Adjusted EPS decreased to $1.05 from $1.32.

$PRGO {{ '2017-05-23T13:59:54+0000' | timeago}} • Webcast

For 2Q17, $PRGO expects Opex to be higher due to the timing of growth investments in R&D across the businesses and advertising and promotion investments in the CHC International business. Administrative expenses are targeted to be higher in 2Q17 due to expenses related to the recently completed filings as well as legal and other professional fees.

$PRGO {{ '2017-05-23T13:50:52+0000' | timeago}} • Webcast

$PRGO updated its 2017 adjusted EPS outlook to $4.15-4.50 from the previous outlook of $6.30-6.65. This guidance excludes Tysabri, which was sold in March 2017 to Royalty Pharma. For calendar year 2017, CHC Americas segment sales are expected to be about $2.4Bil, CHC International to be about $1.4Bil and Rx Pharma unit sales to be about $925MM.

$PRGO {{ '2017-05-23T13:06:46+0000' | timeago}} • Announcement

$PRGO expects 2017 net sales of $4.6-4.8Bil. The company expects calendar 2017 EPS of $0.22-0.57 and adjusted EPS of $4.15-4.50, including contributions from the Israel Active Pharmaceutical Ingredients (API) business.

$PRGO {{ '2017-05-23T13:01:21+0000' | timeago}} • Announcement

$PRGO reported a wider loss in calendar 4Q16 due to impact of change in fair value of Tysabri royalty stream. Net loss widened to $1.36Bil or $9.48 per share from $218MM or $1.51 per share last year. Sales slid 2% to $1.33Bil, on sale of the U.S. VMS business in 3Q16, which was included in 2015. Adjusted EPS decreased 11% to $1.24.

$PRGO {{ '2017-05-23T12:59:14+0000' | timeago}} • Webcast

$PRGO filed a Jumbo 10-K with the SEC, which included the financial information for FY14 and FY15 and the transition period from June 28, 2015 to December 31, 2015. The company also filed the amended 10-Qs for the first, second and third quarters of 2016.

$PRGO {{ '2017-05-08T13:01:21+0000' | timeago}} • Announcement

$PRGO appointed Rolf Classon and Adriana Karaboutis to the company's BoD. Classon and Karaboutis began their service upon Ellen Hoffing's resignation, following their appointment by the Board to serve as directors of the company.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
PRGO (Perrigo Company Public Limited Company)
Wednesday, May 31 2017 - 12:30pm
ADK (AdCare Health Systems, Inc.)
Tuesday, May 16 2017 - 1:00pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, May 10 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
MNK (Mallinckrodt Public Limited Company)
Monday, May 8 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
CBM (Cambrex Corporation.)
Thursday, May 4 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
ADK (AdCare Health Systems, Inc.)
Friday, March 24 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm

AlphaGraphics you may like